TNF and metabolic dysfunction-associated steatotic liver disease: Seven patients (39%) in the IBD-NAFLD group and 11 patients (55%) in the IBD-only group were using biologic drugs, most of which were TNF-alpha inhibitors (i.e., infliximab, adalimumab, golimumab), while only two (10%) were on vedolizumab, an anti-integrin drug.